Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of CCR6 (unknown origin) at 10 uM relative to control
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human CCR6 at 10 uM relative to control
Antagonist activity against CCR6 (unknown origin) assessed as inhibition of beta-arrestin 2 recruitment at 10 microM by beta arrestin assay relative to control
Agonist activity against CCR6 (unknown origin) assessed as induction of beta-arrestin 2 recruitment at 10 microM by beta arrestin assay relative to control
Biological Assay from US Patent US11208377: "3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof"
Assay data:119 Active, 119 Activity ≤ 1 µM, 119 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
FLIPR Assay from US Patent US9090596: "Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies"
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
In Vitro Affinity Assay from US Patent US9580412: "Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases"
Assay data:21 Active, 20 Activity ≤ 1 µM, 21 Tested
PRESTO-Tango GPCRome screening (CCR6)
SummaryRelated BioAssays by Target
Antagonist activity at CCR6 (unknown origin) assessed as inhibition of ligand-induced calcium flux measured upto 10 uM
Antagonist activity at CCR6 in human CD4-positive T cells assessed as inhibition of CCL20-induced cytosolic calcium flux up to 10 uM by calcium 4 dye based FLIPR TETRA analysis
Antagonist activity at CCR6 in human CD4-positive cells assessed as inhibition of CCL20-induced calcium signal up to 10000 nM by FLIPR assay
Antagonist activity at human Gi/G0-coupled CCR6 receptor expressed in CHOK1 cells assessed as inhibition of CCL20-induced beta arrestin2 recruitment at 500 nM preincubated for 30 mins followed by CCL20 stimulation and measured after 90 to 180 mins by pathhunter assay
Antagonist activity at human CCR6
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Antagonist activity at human CCR6 expressed in CHOK1 cells assessed as inhibition of CCL20-induced cAMP accumulation at 10 uM preincubated for 30 mins followed agonist addition measured after 30 to 60 mins
Antagonist activity at CCR6 (unknown origin)
Agonist activity at CCR6 (unknown origin)
Inhibition of human CCR6 in human whole blood assessed as decrease in recombinant human CCL20-induced ERK phosphorylation after 5 mins by flow cytometry
Inhibition of human CCR6 expressed in human B cells assessed as decrease in recombinant human CCL20-dependent cell migration at 0.1 to 1 uM incubated for 75 mins by Transwell assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on